Epstein-Barr Virus (LMP)Catalog number: EB100
The antibody cocktail is positive for the latent membrane protein-1 (LMP1) of the Epstein-Barr Virus. It strongly reacts with EBV-infected lymphoblastoid cell lines and infected B-cell immunoblasts in infectious Mononucleose and atypical lymphoproliferations in immunosuppressed patients. It is positive in app. 25-30 % undifferentiated nasopharyngeal carcinomas and in 40-50% of Hodgkin's diseases. Due to the lack of LMP in Burkitt's disease the cocktail is unreactive with these cells. Epstein Barr Virus is a member of the herpes viridae family and is involved in the development of infectious mononucleosis. EBV infections are also discussed in connection with the induction of several tumours. Generally EBV is found in Burkitt's lymphoma and in nasopharyngeal carcinoma. Additionally it is found in 40-50 % of Hodgkin lymphoma and app. 20-30 % of anaplastic CD30+ large cell lymphoma. Hydrophilic C-terminal end of the 60 kDa late membrane protein 1 of Eppstein Barr Virus.
Immunogen: Fusion protein of beta-galactosidase and EBV-late membrane antigen
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Concentration: 50 µg/ml
Species Reactivity: Epstein Barr Virus
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:10 - 1:20
Pre-Treatment: For pre-treatment Pronase (0,1%) is recommended, however unmasking on citrate basis (DE000) or glycol basis (DE007) will also improve the staining intensity. Cryostat sections and cell smears should be fixed with acetone since the antibody will not react with native antigen.
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J. 6; 2743-2453. 2. 2. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., et al. (1990) Epstein-Barr virus in nasal T-cell lymphomaas in patients with lethal midline granuloma. Lancet 335; 128-130. 3. Herbst H. Dallenbach F. Hummel M., Niedobietek G. Finn T., Young L.S., et al. (19919 Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphoma. 4. Murray P.G., Young L.S., Rowe M., and Crocker J. (1992) Immunohistochemical demonstration of the Epstein-Barr virus encoded latent membrane protein in paraffin sections of Hodgkin's disease. J. Pathol. 166; 1-5.
Safety Datasheet(s) for this product:
Epstein-Barr Virus (LMP)
$435.00Add To Cart